No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...

Moderna conducts phase 3 trial for norovirus vaccine as cases rise in the U.S., with results expected in late 2025 or early 2026.

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Even so, broadening the range of trials’ participants can be practically useful, because they may lead to new medical ...

The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

As Moderna (NASDAQ: MRNA ... In particular, its seven oncology drugs in mid-to-late-stage clinical trials, especially the six of those that are individualized neoantigen therapies (INTs), are ...

Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the ...